The Life Sciences Report

Other Streetwise Reports

The Gold Report The Energy Report The Life Sciences Report The Mining Report

Today's Featured Company

Neuralstem Inc.: (CUR:NYSE.MKT) Neuralstem Inc. is focused on developing and commercializing treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. The company has developed and maintains a portfolio of patents and patent applications that form the base of its research and development efforts in neural stem cell research, small molecule research and related technologies. More >

Streetwise Expert Interviews

Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector

An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers. Raghuram "Ram" Selvaraju, managing director and head of equity healthcare research at Aegis Capital, begs to differ. His research has uncovered small- and micro-cap companies developing sophisticated platforms in the molecular diagnostics space that are destined for significant revenue growth and profits. In his first of three interviews with The Life Sciences Report, Selvaraju lays out a handful of names with powerful technologies on the cusp of investor acceptance as huge growth plays. (12/5/13) More >

Newsletter Briefs

"DRIO is developing a very interesting approach to diagnostics at the level of data capture." (12/5/13) LabStyle Innovations Corp. - The Life Sciences Report Interview with Ram Selvaraju More >

"NBS has the potential to become a major player in the stem cell industry." (11/25/13) NeoStem Inc. - Glen Woods, Seeking Alpha More >

"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >

"I am encouraged by CYTR's interim clinical trial results to date." (11/19/13) CytRx Corp. - John Mylant, Seeking Alpha More >

"The year 2014 is clearly going to be a defining one for ATHX." (11/18/13) Athersys Inc. - Bio StocksElite, Seeking Alpha More >

"BDSI is quite an interesting company; we expect Bunavail to be approved." (11/26/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Michael Hay More >

Expert Analysis

"Results in 2014 from ATHX's phase 2 studies could rerate the stock." (12/2/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"VRS' Aura continues to be recognized as one of the leading novel medical technologies." (12/2/13) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research More >

"Major alliances reduce execution risk for MSB's late-stage pipeline." (11/26/13) Mesoblast Ltd. - Michael Aitkenhead, Edison Investment Research More >

"CTH's concept is simple and the path to commercialization has been validated; we like the story." (11/26/13) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >

"Walgreens' procurement of OCLS' Puracyn products is positive." (11/25/13) Oculus Innovative Sciences Inc. - Dan Trang, Stonegate Securities More >

"NBS has the potential to become a major player in the stem cell industry." (11/25/13) NeoStem Inc. - Glen Woods, Seeking Alpha More >